NCT06262633Recruiting
A Multi-centre Trial on Targeted Microwave Ablation (TMA) for Localized Prostate Cancer
A Multi-centre Trial on Targeted Microwave Ablation (TMA) for Localized Prostate Cancer Using Organ Based Tracking (OBT) Navigation
Source: ClinicalTrials.gov · Last updated 6 May 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This study is to investigate the efficacy of Targeted Microwave Ablation (TMA) under MRI-Ultrasound fusion and organ-based tracking (OBT) navigation in localized prostate cancer (PCa) in a multi-centre trial.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 103 (estimated)
- First submitted
- 21 Jan 2024
- Start date
- 15 Mar 2024
- Primary completion date
- 30 Apr 2026
- Lead sponsor
- Chinese University of Hong Kong
- Diseases
- Prostate cancer
- NCT number
- NCT06262633
What you commit to
- Study type: Interventional
- Planned participants: 103
- From 15 Mar 2024 to the primary completion date, 30 Apr 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients with previous treatment of prostate cancer
- Patients with prior pelvic radiotherapy for prostate cancer or other cancer
Other illness
- . Patients with \>2 areas (MRI-visible or invisible) of prostate cancer
- Patients with Gleason score 4+4 or any Gleason pattern 5 cancer
- Patients with definite cT3 or above disease on imaging (prostate capsular contact without definite extra-capsular extension is acceptable)
- Patients with bladder pathology including bladder stone and bladder cancer
- Patient with a suspected COVID-19 disease or an active SARS-CoV-2 infection.
Lab values
- Patients unfit for MRI exam or MR gadolinium contrast (e.g. estimated glomerular filtration rate (eGFR) of \<50 ml/min)
Other
- Patients not fit for general or spinal anaesthesia
- Patients with coagulopathy that cannot be corrected
- Patients on anticoagulants or antiplatelets that cannot be stopped (Low dose Aspirin, e.g. 80-100mg, is acceptable and no need to stop before or during TMA treatment)
- Patients with maximal length of target lesion \>15mm
- Patients with MRI-visible or invisible lesion within 10mm from rectum or 10mm from sphincter on MRI
- Patients with systematic cores showing any Gleason 4 pattern PCa which are not adjacent to the target lesions (1 core of pure Gleason 3 pattern PCa on systematic cores in contralateral lobe is acceptable)
- Patients with known urethral stricture
Who the study is looking for
- Men aged between 45 - 75 years
- Life expectancy \> 10 years upon recruitment
- Able to understand the trial and can provide informed and written consent, dated and signed before the enrollment and before any exam required by the trial
- Localized low or intermediate risk prostate cancer diagnosed on MRI-Ultrasound fusion targeted biopsy
- Organ-confined prostate cancer on MRI
- PSA \< 20 ng/mL
- 1-2 MRI visible lesion present and size ≤15mm, with targeted biopsy showing:
- ISUP grade group 2 or 3, or
- ISUP grade group 1 with tumor size ≥10mm
Age in the registry: 45 years to 75 years · Sex: Male · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Peter Ka-Fung CHIU Coordinator of this site? Confirm its status | Shatin | Hong Kong SAR China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.